The potential listing of Genting Bhd’s 20.7%-owned Alzheimer’s drugs company on Nasdaq could provide a catalyst to the share price of the Malaysian conglomerate.
At a valuation of US$15bil (RM65.9bil), the initial public offering (IPO) of Singapore-based TauRx Pharmaceuticals Ltd could potentially add RM10.4bil, or 40%, to the sum-of-parts (SOP) for Genting based on Maybank Investment Bank (IB) Research analysis.
“This implies a 40% upside from this one listing alone,” Maybank IB Research said in its report.
For Free Signals and other KLSE online updates, click here OR Give A Missed Call : +60350219047 Follow Us On Twitter : www.twitter.com/epicresearchmy Like Us On Facebook : www.facebook.com/EpicResearchMalaysia Need Any Assistance Feel Free To Mail Us at : info@epicresearch.my
At a valuation of US$15bil (RM65.9bil), the initial public offering (IPO) of Singapore-based TauRx Pharmaceuticals Ltd could potentially add RM10.4bil, or 40%, to the sum-of-parts (SOP) for Genting based on Maybank Investment Bank (IB) Research analysis.
“This implies a 40% upside from this one listing alone,” Maybank IB Research said in its report.
For Free Signals and other KLSE online updates, click here OR Give A Missed Call : +60350219047 Follow Us On Twitter : www.twitter.com/epicresearchmy Like Us On Facebook : www.facebook.com/EpicResearchMalaysia Need Any Assistance Feel Free To Mail Us at : info@epicresearch.my
No comments:
Post a Comment